Suppr超能文献

碳酸酐酶IX的靶向抗癌前乙烯砜共价抑制剂。

Targeted anticancer pre-vinylsulfone covalent inhibitors of carbonic anhydrase IX.

作者信息

Vaškevičius Aivaras, Baronas Denis, Leitans Janis, Kvietkauskaitė Agnė, Rukšėnaitė Audronė, Manakova Elena, Toleikis Zigmantas, Kaupinis Algirdas, Kazaks Andris, Gedgaudas Marius, Mickevičiūtė Aurelija, Juozapaitienė Vaida, Schiöth Helgi B, Jaudzems Kristaps, Valius Mindaugas, Tars Kaspars, Gražulis Saulius, Meyer-Almes Franz-Josef, Matulienė Jurgita, Zubrienė Asta, Dudutienė Virginija, Matulis Daumantas

机构信息

Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.

Latvian Biomedical Research and Study Centre, Riga, Latvia.

出版信息

Elife. 2024 Dec 17;13:RP101401. doi: 10.7554/eLife.101401.

Abstract

We designed novel pre-drug compounds that transform into an active form that covalently modifies particular His residue in the active site, a difficult task to achieve, and applied to carbonic anhydrase (CAIX), a transmembrane protein, highly overexpressed in hypoxic solid tumors, important for cancer cell survival and proliferation because it acidifies tumor microenvironment helping invasion and metastases processes. The designed compounds have several functionalities: (1) primary sulfonamide group recognizing carbonic anhydrases (CA), (2) high-affinity moieties specifically recognizing CAIX among all CA isozymes, and (3) forming a covalent bond with the His64 residue. Such targeted covalent compounds possess both high initial affinity and selectivity for the disease target protein followed by complete irreversible inactivation of the protein via covalent modification. Our designed prodrug candidates bearing moderately active pre-vinylsulfone esters or weakly active carbamates optimized for mild covalent modification activity to avoid toxic non-specific modifications and selectively target CAIX. The lead inhibitors reached 2 pM affinity, the highest among known CAIX inhibitors. The strategy could be used for any disease drug target protein bearing a His residue in the vicinity of the active site.

摘要

我们设计了新型前药化合物,这些化合物可转化为活性形式,与活性位点的特定组氨酸残基发生共价修饰,这是一项难以实现的任务,并将其应用于碳酸酐酶(CAIX),一种跨膜蛋白,在缺氧实体瘤中高度过表达,对癌细胞的存活和增殖很重要,因为它可酸化肿瘤微环境,有助于侵袭和转移过程。所设计的化合物具有多种功能:(1)识别碳酸酐酶(CA)的伯磺酰胺基团;(2)在所有CA同工酶中特异性识别CAIX的高亲和力部分;(3)与His64残基形成共价键。这种靶向共价化合物对疾病靶蛋白具有高初始亲和力和选择性,随后通过共价修饰使蛋白完全不可逆失活。我们设计的前药候选物带有适度活性的前乙烯砜酯或弱活性的氨基甲酸酯,针对温和的共价修饰活性进行了优化,以避免有毒的非特异性修饰并选择性靶向CAIX。先导抑制剂的亲和力达到2 pM,在已知的CAIX抑制剂中是最高的。该策略可用于活性位点附近带有组氨酸残基的任何疾病药物靶蛋白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6925/11651660/d7f15a70eade/elife-101401-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验